this information is out there on Nuvilex's website and on the sec documents....and I know the true longs already know this...there is plenty more...but so many want everyone to do their homework for them...I usually won't ....because I don't like laziness ...but if this will help you new guys to understand a little more it is worth it...please go do some DD...you won't believe the confidence you will gain by doing it....you won't have any more questions and you won't sell a single share of your Nuvilex stock...
Bavarian Nordic (BAVA.CO) holds the patents for Cell-in-Box and Vac-in-a-Box....to which Bio Blue Bird AG (BBB) licensed the rights to them...in the first purchase agreement Nuvilex was to buy the parent co. SG Austria who's Private Limited’s wholly-owned was Bio Blue Bird AG....Nuvilex wanted the worldwide rights that BBB had...but in the Third Addendum to the purchase agreement the terms were changed...
here they are:
Third Addendum to Asset Purchase Agreement
On or about July 10, 2013, with an effective date of June 25, 2013, the Registrant and SG Austria Private Limited (“SG Austria”) notified shareholders that they had executed and completed the majority of tasks necessary to fulfill and complete the Third Addendum (the “Third Addendum”) to the original Asset Purchase Agreement between the companies, dated May 26, 2011. Under the terms of the Third Addendum, the Registrant acquired 100% of the equity interests in Bio Blue Bird AG (BBB) from BBB's parent company SG Austria and, in addition, received a 14.5% equity interest in SG Austria for payments made to date.
The Registrant paid $1.5 million USD in cash to acquire BBB. Funding was accomplished through a private placement sale to accredited investors of 12,000,000 shares of the Company's restricted common stock for $0.125 per share. The original Agreement planned for 100,000,000 shares of the common stock of the Registrant (the “Escrow Shares”) to be issued in connection with a transaction to acquire all assets and stock (the equity interests) of SG Austria. The Third Addendum instead provides that the Registrant would acquire 100% of the equity interests in BBB, 14.5% of the equity interest in SG Austria, and Escrow Shares would be returned to the Registrant's treasury.
BBB is now a debt-free wholly-owned subsidiary of the Registrant and provides exclusive worldwide licenses for the use of encapsulation for oncology, through patents licensed by BBB from Bavarian Nordic (BAVA.CO, Listed on NASDAQ OMX Copenhagen), a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases. This licensing enables the Registrant to carry out any form of living-cell encapsulation-based cancer treatment and encapsulation of virus expressing cells for treating diseases.
so now nuvilex owning 100% of BBB gave us the worldwide rights...
and we did not have to buy 100% of the parent co..SG Austria...for all those shares so they got returned to us and in the process ended up owning 14.5% ( BBB's % )of the SG Austria...
SG Austria Pte Ltd (operating: Austrianova Singapore Pte Ltd.) is who is doing all the R&D...hence why we are working with them to further Cell-in-a-Box....
SG Austria (operating under Austrianova Singapore Pte Ltd), was established in 2007; whilst based in Singapore’s top research biotech hub, Biopolis, it has a global footprint. In addition to offering Cell-in-a-Box and Bac-in-a-Box business to business, SG Austria is also developing it's own oncology product which has already been in multiple, sucessful clinical trials. SG Austria also provides services around the GMP manufacturing of encapsulated cell products.
so we also bought the licensing from them to use the trademark:
Licensing Agreement
On July 10, 2013, with an effective date of June 25, 2013, the Registrant negotiated and obtained a Licensing Agreement, to further expand the interests of the Company which is entirely unrelated to the Third Addendum and purchase of Bio Blue Bird AG described above.
This Licensing Agreement with Austrianova Singapore Pte Ltd. (“ASPL” or “ANS”), grants to the Registrant an exclusive worldwide license to use the Cell-In-A-Box® trademark and its associated technology.
Nuvilex Inc said that BBB has exclusive universal licenses for the pancreatic cancer treatment based on live-cell encapsulation. These licenses offer rights to use the live-cell encapsulation for development of treatments for cancer types based on any cell type encapsulated.
The company will be able to use technology for the pancreatic cancer trials. The purchase price paid is $1.5 million.
Jan. 30, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has received its share issuance from SGAustria Pte. Ltd. (Austrianova), who owns Austrianova Singapore Pte. Ltd. (Austrianova Singapore), that equates to a 14.5% equity interest in Austrianova.
The issuance of shares by Austrianova fulfils an obligation by Austrianova to Nuvilex that was part of the Asset Purchase Agreement between both companies pertaining to the acquisition of Bio Blue Bird AG and, with it, the worldwide exclusive rights for Nuvilex to use Austrianova's Cell-in-a-Box(TM) cellulose-based live-cell encapsulation technology for the development of treatments for all types of cancer. Nuvilex has also obtained from Austrianova Singapore the exclusive worldwide rights to use the Cell-in-a-Box(TM) technology for the development of treatments for diabetes.
we also proceeded to purchase the rights to use it for Diabetes...
NEW YORK, NY--(Marketwired - Nov 19, 2013) - Nuvilex, Inc. (OTCQB: NVLX) recently acquired the exclusive worldwide rights to a proprietary cellulose-based live-cell encapsulation technology for developing treatments for all types of cancer, most notably pancreatic cancer. This acquisition should put the company and cell encapsulation-based therapies on the map if its future Phase 3 clinical trials in patients with advanced, inoperable pancreatic cancer produce similar data to that seen in two separate early-phase trials in this disease.
But, Nuvilex didn't stop there. Executives then went out and raised enough capital at a price above the current share price to purchase the same exclusive worldwide rights to the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes. When all is said and done, it is the diabetes acquisition that could make Nuvilex a household name.
bull
